This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ABT-107

AbbVie Inc.

Drug Names(s): ABT-107

Description: ABT-107 is an a7-subtype neuronal nicotinic receptor (NNR) agonist, which has shown promise in preclinical models relevant for the treatment of cognitive deficits. Alpha-7 nicotinic acetylcholine receptors are thought to be involved in memory, cognition, synaptic plasticity, and neuronal survival. They not only mediate cholinergic transmission but also influence signaling at noncholinergic synapses (such as glutamate and serotonin). In addition, they may mediate dopamine release in response to nicotine, particularly in the nucleus accumbens, part of the classic reward pathway.

Deal Structure: From 1999 to 2003 NeuroSearch and Abbott collaborated within the field of Neuronal Nicotine Acetycholine Receptors (NNRs). According to the terms of the license agreement, Abbott has all rights to ABT-107 and will finance all costs relating to the development and commercialization of the drug. NeuroSearch will receive milestone payments as well as royalties on Abbotts global sales, if the drug is successfully commercialized.

Partners: NeuroSearch A/S


ABT-107 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug